Erbelding EJ, Post D, Stemmy E, Roberts PC, et al. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis 2018 Feb 28
A priority for the National Institute of Allergy and Infectious Diseases (NIAID) is development of an influenza vaccine providing durable protection against multiple influenza strains, including those that may cause a pandemic, i.e., a universal influenza vaccine. To invigorate research efforts, NIAID developed a strategic plan focused on knowledge gaps in three major research areas, as well as additional resources required to ensure progress towards a universal influenza vaccine. NIAID will use this plan as a foundation for future investments in influenza research and will support and coordinate a consortium of multidisciplinary scientists focused on accelerating progress towards this goal.
See Also:
Latest articles in those days:
- [preprint]Susceptibility of bovine respiratory and mammary epithelial cells to avian and mammalian derived clade 2.3.4.4b H5N1 highly pathogenic avian influenza viruses 22 hours ago
- Genetic Diversity of H10N3 Avian Influenza Virus Isolated from Anhui Province, China 23 hours ago
- Molecular origion of human infection with a novel avian influenza A H10N3 virus in China, 2021 23 hours ago
- Clade 2.3.4.4b but not historical clade 1 HA replicating RNA vaccine protects against bovine H5N1 challenge in mice 23 hours ago
- GGCX promotes Eurasian avian-like H1N1 swine influenza virus adaption to interspecies receptor binding 23 hours ago
[Go Top] [Close Window]